肾细胞癌
本文综述了肾细胞癌的流行病学、病理学和诊断,讨论了从局限期到转移性疾病的当前管理策略证据。辅助治疗方面,帕博利珠单抗是首个在辅助治疗中达到总生存获益的疗法;晚期疾病中免疫检查点抑制剂已成为标准治疗。文章还讨论了转移性肾细胞癌管理的争议、非透明细胞亚型的治疗及未来研究方向。
要点
- 帕博利珠单抗是首个在肾细胞癌辅助治疗中达到总生存获益的疗法。
- 免疫检查点抑制剂已被标志性试验确立为晚期肾细胞癌的标准治疗。
- 转移性肾细胞癌管理仍存争议,包括风险评估模型用于疾病分层和一线治疗选择。
核心结论
- 过去十年肾细胞癌管理格局发生实质性演变,局限期和晚期疾病生存均得到改善。
研究设计与样本
- 综述,讨论肾细胞癌从局限期到转移性疾病的当前管理策略证据。
主要发现
- 帕博利珠单抗是首个在辅助治疗中达到总生存获益的疗法。
- 标志性试验已确立免疫检查点抑制为晚期肾细胞癌的标准治疗。
- 转移性肾细胞癌管理存在争议,包括风险评估模型用于疾病分层和一线治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The landscape of the management of renal cell carcinoma has evolved substantially in the last decade, leading to improved survival in localised and advanced disease. We review the epidemiology, pathology, and diagnosis of renal cell carcinoma and discuss the evidence for current management strategies from localised to metastatic disease. Developments in adjuvant therapies are discussed, including use of pembrolizumab-the first therapy to achieve overall survival benefit in the adjuvant setting. The treatment of advanced disease, including landmark trials that have established immune checkpoint inhibition as a standard of care, are also reviewed. We also discuss the current controversies that exist surrounding the management of metastatic renal cell carcinoma, including the use of risk assessment models for disease stratification and treatment selection for frontline therapy. Management of non-clear cell renal cell carcinoma subtypes is also reviewed. Future directions of research, including a discussion of ongoing clinical trials and the need for reliable biomarkers to guide treatment in kidney cancer, are also highlighted.
引用
- Young M, Jackson-Spence F, Beltran L, et al. Renal cell carcinoma. Lancet. 2024. PMID: 39033764. doi:10.1016/S0140-6736(24)00917-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。